About
Immune Modulation
Immunyx Pharma is a drug development company focused on modulating neutrophil function to treat disease. Using the company's platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure. Immunyx Pharma's neutrophil-targeting technology is based on years of basic and translational research by professors Zvika Granot and Zvi Fridlender at the Hebrew University.
Identity
| Name | Immunyx Pharma |
|---|---|
| Slug | immunyx-pharma |
| Former names | NEUTROPHIX |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4K_e6YEKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Jerusalem, Israel |
Web & social
| Website | https://www.immunyx.com |
|---|---|
| https://www.linkedin.com/company/72102910 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
immunotherapybiotechnologypharmaceuticalscell-therapytargeted-therapydrug-developmenttreatmentspharma-companies
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}